Boston, United States
Ratio Therapeutics, established in 2021, is positioning itself as "The Partner of Choice for Next-Generation Radiopharmaceutical Precision Medicine" by utilizing a suite of innovative technologies aimed at revolutionizing cancer treatment.
This early clinical phase pharmaceutical company is developing best-in-class targeted radiotherapeutics designed to treat a broad array of cancer targets. Its proprietary Trillium™ targeting scaffold combines pharmacokinetic modulation with state-of-the-art chelation technology, enabling the creation of small molecule targeting agents. These agents are designed for both imaging and therapeutic radioisotopes, commonly known as "theranostics."
By utilizing a tunable platform and executing small-scale imaging trials in patients, Ratio Therapeutics ensures accelerated and de-risked compound selection. Despite limited information on their previous funding rounds, the company remains a promising candidate for investors looking to tap into advanced cancer treatment solutions. Investors have yet to publicly disclose any recent investments, opening potential opportunities for new stakeholders to engage with this burgeoning innovator in precision medicine.
